1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

UCB propels Vimpat monotherapy along Keppra path, but can it beat Keppra?

 
• By Pial Ganguli

UCB has reported positive Phase III data that shows that its anti-epileptic drug, lacosamide (Vimpat) performs better when used as monotherapy than when used an adjunct. This data, the company said, will be included as part of a supplemental new drug application (sNDA) submission to the US FDA in the second half of this year.

UCB has reported positive Phase III data that shows that its anti-epileptic drug, lacosamide (Vimpat) performs better when used as monotherapy than when used an adjunct. This data, the company said, will be included as part of a supplemental new drug application (sNDA) submission to the US FDA in the second half of this year.

The data means that UCB may be able pursue a similarly deep incremental market penetration with Vimpat as with an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.